Circulation:房颤的遗传易感性、临床危险因素负担和终生风险分析!

2017-11-13 xing.T MedSci原创

在这项社区为基础的队列中,房颤的终生风险为37%。多基因房颤风险的估计是可行的,加上临床危险因素负担可以解释长期房颤风险的严重梯度。

考虑遗传易感性和临床危险因素负担的房颤发生的长期几率尚不清楚。近日,心血管领域权威杂志Circulation上针对这一问题发表了一篇研究文章。

研究人员估计了来自于社区为基础的Framingham心脏研究的个体房颤的终生风险,利用大约1000个房颤相关的单核苷酸多态性来推断房颤的多基因风险。研究人员采用由身高、体重、收缩压和舒张压、吸烟状况、抗高血压药物、糖尿病心肌梗死病史及心衰史组成的经验证的房颤发生风险评分来计算每一个人的临床危险因素负担。研究人员估计了房颤在多基因和临床危险因素方面的终生风险。

在4606名无房颤的年龄为55岁的受试者中,580人发生房颤(平均随访9.4年;第25-75百分位数为4.4-14.3年)。55岁后房颤的终生风险为37.1%,受多基因和临床危险因素负担的影响较大。在无房颤的年龄为55岁的受试者中,多基因和临床风险为较低三分位数组的受试者发生房颤的终生风险为22.3%(95%可信区间[CI]为15.4%-29.1%),而多基因和临床风险为较高三分位数组的受试者风险为48.2%(95%CI为41.3%-55.1%)。将遗传易感性进行调整后,较低的临床危险因素负担与较晚的房颤发病有关(P<0.001)。

在这项社区为基础的队列中,房颤的终生风险为37%。多基因房颤风险的估计是可行的,加上临床危险因素负担可以解释长期房颤风险的严重梯度。

原始出处:

Lu-Chen Weng,et al. Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. Circulation. 2017. https://doi.org/10.1161/CIRCULATIONAHA.117.031431

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032101, encodeId=0d1d20321011a, content=<a href='/topic/show?id=be0ce8189e9' target=_blank style='color:#2F92EE;'>#终生风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78189, encryptionId=be0ce8189e9, topicName=终生风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Sep 25 16:31:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454706, encodeId=1aec1454e063b, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460539, encodeId=c47514605391c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260975, encodeId=22b32609e578, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Nov 13 10:23:44 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260944, encodeId=f40626094494, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Nov 13 07:37:49 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032101, encodeId=0d1d20321011a, content=<a href='/topic/show?id=be0ce8189e9' target=_blank style='color:#2F92EE;'>#终生风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78189, encryptionId=be0ce8189e9, topicName=终生风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Sep 25 16:31:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454706, encodeId=1aec1454e063b, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460539, encodeId=c47514605391c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260975, encodeId=22b32609e578, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Nov 13 10:23:44 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260944, encodeId=f40626094494, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Nov 13 07:37:49 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032101, encodeId=0d1d20321011a, content=<a href='/topic/show?id=be0ce8189e9' target=_blank style='color:#2F92EE;'>#终生风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78189, encryptionId=be0ce8189e9, topicName=终生风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Sep 25 16:31:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454706, encodeId=1aec1454e063b, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460539, encodeId=c47514605391c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260975, encodeId=22b32609e578, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Nov 13 10:23:44 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260944, encodeId=f40626094494, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Nov 13 07:37:49 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032101, encodeId=0d1d20321011a, content=<a href='/topic/show?id=be0ce8189e9' target=_blank style='color:#2F92EE;'>#终生风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78189, encryptionId=be0ce8189e9, topicName=终生风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Sep 25 16:31:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454706, encodeId=1aec1454e063b, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460539, encodeId=c47514605391c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260975, encodeId=22b32609e578, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Nov 13 10:23:44 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260944, encodeId=f40626094494, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Nov 13 07:37:49 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
    2017-11-13 flysky120

    学习一下知识了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2032101, encodeId=0d1d20321011a, content=<a href='/topic/show?id=be0ce8189e9' target=_blank style='color:#2F92EE;'>#终生风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78189, encryptionId=be0ce8189e9, topicName=终生风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Sep 25 16:31:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454706, encodeId=1aec1454e063b, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460539, encodeId=c47514605391c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Nov 14 22:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260975, encodeId=22b32609e578, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Nov 13 10:23:44 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260944, encodeId=f40626094494, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Nov 13 07:37:49 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
    2017-11-13 明月清辉

    谢谢分享.学习了

    0

相关资讯

JAHA:房颤和脓毒症患者抗凝治疗的出血并发症!

在败血症诊断时服用华法林治疗的AF患者在脓毒症后3个月内出血率增加。华法林的使用与死亡率较低相关,尽管血栓栓塞率几乎相当。

脑梗:一定要检查有没有房颤!

国内外指南均非常重视在不明原因卒中患者中反复进行动态心电图监测,以便筛查出阵发性房颤。例如,我国2014年中国缺血性卒中和短暂性脑缺血发作二级预防指南指出,我国首发缺血性卒中或TIA患者中房颤的患病率为11.4%,但国外研究发现,在卒中发生30天内重复心电监测可检出20%的阵发性房颤患者。

SCI REP:半乳糖凝集素-3和hs-CRP 与NSTEMI伴房颤患者临床结局之间的相关性分析!

在既往患有房颤的NSTEMI患者中半乳糖凝集素-3和hs-CRP血浆水平明显升高,但是对不良的临床结局的预测价值有所不同。只有hs-CRP与复合结局的发生风险增加有关。

NEJM:房颤患者PCI后双抗还是三重抗血栓治疗更好?

2017年10月,发表在《N Engl J Med》上的一项多中心试验探究了经皮冠状动脉介入治疗(PCI)后的房颤患者,使用华法林+两种抗血小板药的三重抗血栓治疗和达比加群+ P2Y12抑制剂的双重疗法哪个出血风险更低。试验结果显示:达比加群和P2Y12抑制剂的双重治疗中的出血风险更低。

2017 EHRA/ESC共识文件:心脏瓣膜病相关性房颤的抗栓治疗

2017年11月,欧洲心律学会(EHRA)联合欧洲心脏病学会(ESC)共同发布了心脏瓣膜病相关性房颤的抗栓治疗共识。本文主要总结了该领域的当前进展并针对这些患者的管理提供了基于循证医学的知道建议。

Eur J Clin Pharmacol:非瓣膜性房颤患者初始用药:达比加群还是维生素K拮抗剂?

非维生素K拮抗剂口服抗凝药的引入为房颤卒中预防的重要进展之一。2017年7月,发表在《Eur J Clin Pharmacol》的一项横断面研究调查了非瓣膜性房颤患者确诊后初始达比加群抗凝治疗的特征,并与初始维生素K拮抗剂(VKAs)的患者进行比较。